Good afternoon :)
$
₹
A

ADARx Pharmaceuticals, Inc. Common Stock

ADRX

NASDAQ
A

ADARx Pharmaceuticals, Inc. Common Stock

ADRX

NASDAQ
$17.376.51% (-1.20)
$
₹
$17.376.51% (-1.20)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $2.0B the stock is ranked 2171

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.16
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.

Peers

Peers

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Financials

Financials

Income

Balance Sheet

Cash Flow

0.2
-18
2.1
-22.6
0.7
-25.7
Q2 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2025Q2 2025Q4 2025Q1 2026Q2 2026
Total Revenue00.20-2.140.74
Net Income-15.55-18.09--22.66-25.75
Net Profit Margin--8698.55%--1059.20%-3452.94%
See CostsAll values in $ Million

Frequently asked questions

  1. ADARx Pharmaceuticals, Inc. Common Stock (ADRX) share price today is $17.37 as of October 8, 2026 at 1:29 AM IST. The stock touched a day high of $18.66 and a day low of $17.19.

  2. ADARx Pharmaceuticals, Inc. Common Stock stock trades on NASDAQ under the ticker symbol ADRX.

  3. ADARx Pharmaceuticals, Inc. Common Stock's market capitalization is $2.03B as of October 8, 2026 at 1:29 AM IST.

  4. ADARx Pharmaceuticals, Inc. Common Stock's price-to-earnings (P/E) ratio is N/A as of October 7, 2026.

  5. ADARx Pharmaceuticals, Inc. Common Stock's price-to-book (P/B) ratio is 0 as of October 7, 2026.

  6. Yes, You can buy ADARx Pharmaceuticals, Inc. Common Stock shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy ADARx Pharmaceuticals, Inc. Common Stock shares in three steps: 1. Search ADARx Pharmaceuticals, Inc. Common Stock on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since ADARx Pharmaceuticals, Inc. Common Stock trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in ADARx Pharmaceuticals, Inc. Common Stock (ADRX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.5757 shares at the current price of $17.37.

Loading...